An interventional study of Cognitive Behavioral Therapy and Acceptance and Commitment Therapy in Chronic Pain, Neck Pain and Back Pain, sponsored by Rush University Medical Center. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Rush University Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.
Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 82nd largest by enrollment of the 1,092 interventional ones that give a count, is one of 117 that started in 2023, is one of 803 with no phase, reaches primary completion later than 151 of the 347 other live ones, and was the 1,006th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:
University of Oklahoma · Sites in United States
Ages 18–120
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18+ · Women only
University of Massachusetts, Boston · Sites in United States
Ages 65+
Stanford University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 112 · Phase 3 72 · Phase 4 50
First in 1992; this study’s year is marked. 117 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 408 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 60 across the 1,092 interventional studies, 100 across the 189 observational. Of the 848 that completed or were terminated, 386 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
209 of 1,283 have an industry lead sponsor. The 10 most frequent:
Rush University Medical Center is the lead sponsor of 397 studies on the registry; 60 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Rush University Medical Center has 9 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
139 of the studies in Chronic Pain with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05703178Phase 3Northwestern UniversityWeb-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | 2026-11-30 |
| NCT06091202Phase 3Oregon Health and Science UniversityTele-Collaborative Outreach to Rural Patients With Chronic Pain | 2027-05-01 |
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT03984565Staci Gruber, Ph.D.PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 1,283 studies in Chronic Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic musculoskeletal pain (CP) is a major public health concern. Psychosocial treatments have been shown to be efficacious when compared to largely inert control conditions, but they are characterized by modest effects on primary outcomes. One strategy to boost efficacy is to increase our understanding of treatment mediators. Studies of mediators that directly compare different treatments with each other are needed to determine which mediators are treatment-specific, which are shared across treatments, and which contribute the most to clinical outcomes. Another strategy is to identify the patient characteristics that moderate treatment responses. Research is needed that is guided by theoretical models and that tests moderators across multiple treatments. Identifying subgroups of patients more likely to respond to one or another treatment can advance precision medicine by informing a priori patient-treatment matches that can optimize treatment effects. To accomplish these goals, the authors will conduct a randomized clinical trial to compare the mediators and moderators of the clinical effects of Cognitive-Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Emotional Awareness and Expression Therapy (EAET) on adults with chronic spinal (axial) pain. Following baseline assessment of outcome variables as well as potential mediators and moderators, 460 participants will be randomized to CBT, ACT, EAET, or treatment-as-usual control (TAU). The three treatments will be conducted as individual therapy provided weekly for 8 weeks via telehealth. The researchers will conduct weekly assessments of both potential mediators and outcomes, as well as post-treatment and 6-month follow-up assessments. The goal of the study is to identify the most powerful treatment mechanisms - specific and shared -- and reveal for whom the mediator-outcome pathways are strongest.This project can increase the effects of our psychosocial chronic pain treatments by identifying the most effective treatment mechanisms and by informing patient-treatment matches that can optimize treatment effects.
Chronic musculoskeletal pain (CP) is a major public health concern. A number of psychosocial treatments have emerged in recent decades to help address this problem. These interventions have been shown to be efficacious when compared to largely inert control conditions; however, recent meta-analyses indicate that most of these treatments are characterized by modest effects on primary outcomes. This is a critical shortcoming of these otherwise promising approaches. Rather than attempting to boost efficacy only by developing new and hopefully more powerful interventions, we can also look within our already proven treatments for ways to enhance the magnitude of treatment effects. One strategy is to increase our understanding of treatment mediators. Studies of mediators that directly compare different treatments with each other are needed to determine which mediators are treatment-specific, which are shared across treatments, and which contribute the most to clinical outcomes. The findings from such research could be used to inform adaptations to existing treatment that enhance their benefits. A second strategy for increasing the beneficial effects of existing treatments is to identify the patient characteristics that moderate treatment responses. Research is needed that is guided by theoretical models and that tests moderators across multiple treatments. Identifying subgroups of patients more likely to respond to one or another treatment can advance precision medicine by informing a priori patient-treatment matches that can optimize treatment effects. To accomplish these goals, we will conduct a randomized clinical trial to compare the mediators and moderators of the clinical effects of Cognitive-Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Emotional Awareness and Expression Therapy (EAET) on adults with chronic spinal (axial) pain. Following baseline assessment of outcome variables as well as potential mediators and moderators we will randomize 460 participants to CBT, ACT, EAET, or treatment-as-usual control (TAU). The three treatments will be conducted as individual therapy provided weekly for 8 weeks via telehealth. We will conduct weekly assessments of both potential mediators and outcomes, as well as post-treatment and 6-month follow-up assessments. In addition to comparing the three treatments to each other (and TAU) for overall efficacy, we focus on two specific aims: Aim 1 is to identify mediators that are specific to treatments and those that are shared across treatments. Aim 2 is to identify baseline moderators of specific treatments and general predictors across treatments. This project can increase the effects of our psychosocial chronic pain treatments by identifying the most powerful treatment mechanisms - specific and shared -- and revealing for whom the mediator-outcome pathways are strongest. Via increased understanding of mediator and moderators, more effective pain treatment approaches can be developed, tested, and implemented.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Past 2 years (treated for or having experienced):
Also:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8-session, individual, Cognitive Behavioral Therapy delivered remotely by skilled CBT therapists
Behavioral: Cognitive Behavioral Therapy
8-session, individual, Acceptance and Commitment Therapy delivered remotely by skilled ACT therapists
Behavioral: Acceptance and Commitment Therapy
8-session, individual, Emotional Awareness and Expression Therapy delivered remotely by skilled EAET
Behavioral: Emotional Awareness and Expression Therapy
In this control condition, participants will engage in their usual care for neck/back pain with no additional experimental intervention
Other: Treatment as Usual
CBT endorses a pain management model and teaches people skills to cope with chronic pain.
Also known as: CBT for chronic pain
ACT is based on an acceptance model that seeks to decrease pain avoidance behaviors and enhance engagement in valued, adaptive activities that contribute to fewer pain-related restrictions in functioning.
Also known as: ACT for chronic pain
EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
Also known as: EAET for chronic pain
Participants assigned to TAU will not receive any additional psychosocial treatment beyond the other treatments they were receiving before enrolling in this study.
Also known as: TAU
Brief Pain Inventory (BPI) - Pain Severity
4-item measure of pain severity over past week (range 0 to 10; higher scores = worse pain severity)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Patient-Reported Outcome Measurement Information System (PROMIS) - Pain Interference - Short Form 8a
8-item measure of pain interference over past week (range1 to 5; higher scores = more pain interference)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Patient Global Impression of Change
1-item measure of overall health change since the start of the study (range 1 to 7; higher scores = more health improvement)
Time frame: Weekly during treatment to post-treatment and 6-month follow-up
Patient-Reported Outcome Measurement Information System (PROMIS) - Physical Function - Short Form 10a
4-item measure of current physical function (range 1 to 5; higher scores = poorer physical function)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Patient-Reported Outcome Measurement Information System (PROMIS) - Emotional Distress - Anxiety - Short Form
4-item measure of anxiety symptoms in the past week (range 1 to 5; higher scores = more anxiety symptoms)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Patient-Reported Outcome Measurement Information System (PROMIS) - Emotional Distress - Depression - Short Form
4-item measure of depression symptoms in the past week (range 1 to 5; higher scores = more depression symptoms)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Patient Health Questionnaire - Depression
8-item measure of depression symptoms in the past week (range 0 to 3; higher scores = more depression symptoms)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Patient-Reported Outcome Measurement Information System (PROMIS) - Fatigue - Short Form
4-item measure of fatigue in the past week (range 1 to 5; higher scores = more fatigue)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Patient-Reported Outcome Measurement Information System (PROMIS) - Sleep Disturbance - Short Form
4-item measure of sleep disturbance in the past week (range 1 to 5; higher scores = more sleep disturbance)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Patient-Reported Outcome Measurement Information System (PROMIS) - Emotional Distress - Anger - Short Form 5a
5-item measure of anger in the past week (range 1 to 5; higher scores = more anger)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Positive and Negative Affect Schedule (PANAS) - Positive Affect - Short Form
5-item measure of positive affect in the past week (range 1 to 5; higher scores = more positive affectivity)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Posttraumatic Stress Disorder Checklist (PCL) - Short Form
5-item measure of trauma symptoms in the past week (range 1 to 4; higher scores = worse PTSD symptoms)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Pain Stages of Change Questionnaire (PSOCQ): Preparation and action
13-item measure on current readiness to adopt self-management for pain, Preparation and Action items only (range 1 to 5; higher scores = more ready to change)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Opioid Use
1-item measure on opioid use in past 7 days (range 1 to 7; higher scores = more days)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Employment
3-item measure on current employment (options for current status and qualitative responses)
Time frame: Baseline to post-treatment and 6-month follow-up
Post-Treatment Satisfaction Questionnaire
8-item measure on patient post-treatment satisfaction (range 1 to 10; higher scores = more satisfied - also included qualitative responses)
Time frame: Post-Treatment to 6-Month Follow-Up
Levels of Emotional Awareness Scale (LEAS) - Forms A and B
10-item measure of current emotional awareness (includes qualitative responses); responses coded for levels of emotional awareness; higher = greater awareness; Form A baseline and Form B at post-treatment
Time frame: Baseline
Other Pain Treatments and Health Care Use
2-item measure of health care currently, the past 6 months, and the past 4 weeks (2 items with yes/no responses and remaining range 0 to 4; higher scores = more treatment)
Time frame: Baseline to post-treatment and 6-month follow-up
Inventory of Interpersonal Problems (IIP)
32-item measure of current interpersonal problems (range 0 to 4; higher scores = more interpersonal problems)
Time frame: Baseline to post-treatment and 6-month follow-up
American College of Rheumatology (ACR) Fibromyalgia Diagnostic Criteria - 2011
8-item measure on fibromyalgia symptoms in the past week (items with yes/no responses, a checklist, and remaining range 0 to 3; higher scores = worse fibromyalgia symptoms)
Time frame: Baseline to post-treatment and 6-month follow-up
Psychological Flexibility Scale (PSYFlex)
6-item measure of psychological flexibility in the past week (range 0 to 5; higher scores = higher psychological flexibility)
Time frame: Baseline to post-treatment and 6-month follow-up
The Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) Tool - Part II
9-item measure on substance use in the past week (yes/no responses); higher scores = more use
Time frame: Baseline to post-treatment and 6-month follow-up
Posttraumatic Stress Disorder Checklist (PCL)
20-item measure of PTSD symptoms in the past month (range 0 to 4; higher scores = worse PTSD symptoms)
Time frame: Baseline to post-treatment and 6-month follow-up
Pain Catastrophizing Scale (PCS)-short form
Potential Mediator; 6-item measure of pain catastrophizing (range 0 to 4; higher scores = higher pain catastrophizing)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Pain Self-Efficacy Questionnaire (PSEQ) - Short Form
Potential Mediator; 4-item measure of current pain self-efficacy (range 0 to 6; higher scores = higher pain self-efficacy)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Survey of Pain Attitudes (SOPA): Pain Control, Disability, Harm, Emotion subscales
Potential Mediator; 4, 2-item measures of current pain attitudes (range 0 to 4; higher scores = more of that construct)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Behavioral Activation for Depression (BADS) - Short Form
Potential Mediator; 9-item measure of behavioral activation for depression in the past week (range 0 to 6; higher scores = higher behavioral activation)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Self-Compassion Scale (SCS) - Short Form
Potential Mediator; 12-item measure of situational self-compassion (range 1 to 5; higher scores = less self-compassion)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Chronic Pain Acceptance Questionnaire (CPAQ)
Potential Mediator; 8-item measure of current chronic pain acceptance (range 0 to 6; higher scores = more chronic pain acceptance)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Chronic Pain Values Inventory (CPVI)
Potential Mediator; 6-item measure of current values (checklist responses)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Emotional Approach Coping Scale (EAC) - Short Form
Potential Mediator; 4-item measure of emotional approach coping (range 1 to 4; higher scores = higher emotional approach coping)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Emotional Breakthrough Inventory (EBI)
Potential Mediator; 6-item measure of emotional breakthroughs in the past week (range 0 to 6; higher scores = more emotional breakthroughs)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Psychological Insight Questionnaire (PIQ)
Potential Mediator; 6-item measure of psychological insight in the past week (range 0 to 5; higher scores = more psychological insight)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Brain and Psychological Attributions for Pain
Potential Mediator; 9-item measure of current belief of brain and psychological attributions for pain (range 0 to 4; higher scores = higher belief in brain and psychological attributions for pain)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Pain Anxiety Symptom Scale (PASS)
Potential Mediator; 4-item measure of current pain anxiety symptoms (range 0 to 5; higher scores = worse pain anxiety symptoms)
Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Adverse Events
Potential Mediator; 2-item measure of adverse events in the past week and past 6 months (checklist responses)
Time frame: Weekly during treatment to post-treatment and 6-month follow-up
Working Alliance Inventory (WAI) - Patient
Potential Mediator; 6-item measure of current working alliance (range 0 to 5; higher scores = better working alliance)
Time frame: Weekly during treatment to post-treatment for three treatment arms only
Working Alliance Inventory (WAI) - Therapist - Short Form
Potential Mediator; 6-item measure of current working alliance (range 0 to 5; higher scores = better working alliance)
Time frame: Weekly during treatment to post-treatment for three treatment arms only
Therapist Checklist of Patient Engagement and Homework
Potential Mediator; 4-item measure on current patient engagement (range 0 to 8; higher scores = more patient engagement)
Time frame: Weekly during treatment to post-treatment for three treatment arms only
Treatment Expectancy and Credibility Questionnaire
Potential Mediator; 8-item measure on current treatment expectancy and credibility (range 0 to 10; higher scores = better treatment expectancy)
Time frame: Weekly during treatment to post-treatment for three treatment arms only
PDFs hosted by the registry, ClinicalTrials.gov.
Started Nov 2023 (actual). Primary completion is estimated for Feb 2027, 39 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 39 months is above that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Feb 2027, on Nov 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rush University Medical Center →